Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02669706 · ClinicalTrials.gov registry record
Intravenous Pentamidine for Pneumocystis Jirovecii Pneumonia
A clinical trial, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- 50
- Enrollment target
NCT02669706 is a clinical trial that has completed, run by University of Illinois at Chicago. The registered enrollment target is 50 participants.
The verdict
NCT02669706 has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
Study Summary
The main objective of this study is to assess the safety of administering intravenous (IV) pentamidine for Pneumocystis jirovecii pneumonia (PJP) prophylaxis in adult inpatients with hematologic malignancies and stem cell transplant recipients. There will also be an assessment of patient satisfaction associated with intravenous pentamidine PJP prophylactic therapy.
Interventions
- DRUG Pentamidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2015-03 |
| Est. Completion | 2016-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02669706
The ClinicalTrials.gov registry entry for NCT02669706 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pentamidine is the first listed.
NCT02669706 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02669706 about?
NCT02669706 is a clinical study titled "Intravenous Pentamidine for Pneumocystis Jirovecii Pneumonia". The main objective of this study is to assess the safety of administering intravenous (IV) pentamidine for Pneumocystis jirovecii pneumonia (PJP) prophylaxis in adult inpatients with hematologic malignancies and stem cell transplant recipients. There will also be an assessment of patient satisfactio...
What is the current status of trial NCT02669706?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2015-03. Estimated completion is 2016-06.
What interventions are being tested in trial NCT02669706?
The interventions under investigation include: Pentamidine (DRUG).
Who is sponsoring clinical trial NCT02669706?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.